ClinicalTrials.gg
RecruitingNCT07428499Updated Sep 4, 2026

Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)

A Phase 3 interventional study of ADX-324 Dose Level 1 and ADX-324 Dose Level 2 in Hereditary Angioedema (HAE), Hereditary Angioedema - Type 1 and Hereditary Angioedema - Type 2, sponsored by ADARx Pharmaceuticals, Inc.. Recruiting at 48 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by ADARx Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
90
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 84 studies in Angioedemas, Hereditary with a site in United States — 12 open to participants now, 18 under way, 10 of them phase 3. Angioedemas, Hereditary · United States.

Planned enrollment
25th of 74
90 · median 57
Started
2026
with 2 others
Phase 3
38 of 84
6 open now
Primary completion
2030-06
later than 14 of 17 live
Registered
83rd of 84
by date
Lead sponsor
2 of 84
ADARx Pharmaceuticals, Inc.

Among the 84 studies in Angioedemas, Hereditary with a site in United States, this one is the 25th largest by planned enrollment of the 74 interventional ones that give a count, is one of 3 that started in 2026, is one of 38 in phase 3, reaches primary completion later than 14 of the 17 other live ones, and was the 83rd registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

12 of the 84 studies in Angioedemas, Hereditary with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies in Angioedemas, Hereditary with a site in United States, or all of them as a file.
02

Study summary

Study ADX-324-302 is an extension study for participants who complete the Phase 3 ADX-324-301 trial. The extension study will provide information about the safety and efficacy of additional dosing of ADX-324 in participants with Type I and Type II hereditary angioedema (HAE). The study will also include pharmacodynamic (PD), pharmacokinetic (PK), and health-related quality of life (HRQoL) measurements.

03

Conditions studied

  • Hereditary Angioedema (HAE)
  • Hereditary Angioedema - Type 1
  • Hereditary Angioedema - Type 2
  • HAE

Keywords

  • Hereditary angioedema
  • HAE
  • ADX-324
  • onvuzosiran
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a documented diagnosis of HAE (Type I or II)
  • Completed Study ADX-324-301
  • Have access to an acute therapy to treat HAE attacks (such as plasma derived or recombinant C1-INH concentrate or a BK2-receptor antagonist)

Exclusion criteria

Exclusion Criteria:

  • A negative reaction to study drug in ADX-324-301
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    ADX-324 Dose Level 1

    Drug: ADX-324 Dose Level 1

  • Experimental
    ADX-324 Dose Level 2

    Drug: ADX-324 Dose Level 2

Interventions

06

What researchers measure

Primary outcomes

  1. Safety of ADX-324 in Participants with HAE

    Incidence and severity of treatment-emergent adverse events

    Time frame: Month 36

Secondary outcomes

  1. Efficacy of ADX-324 in Preventing HAE Attacks

    Number of Investigator-confirmed HAE attacks per month

    Time frame: Month 36

07

Study locations

3 of 48 sites recruiting
  • ADARx Clinical Site
    Litchfield Park, Arizona 85340, United States
    Not yet recruiting
  • ADARx Clinical Site
    Little Rock, Arkansas 72205, United States
    Not yet recruiting
  • ADARx Clinical Site
    San Diego, California 92122, United States
    Not yet recruiting
  • ADARx Clinical Site
    Walnut Creek, California 94598, United States
    Not yet recruiting
  • ADARx Clinical Site
    Orlando, Florida 32807, United States
    Not yet recruiting
  • ADARx Clinical Site
    Chevy Chase, Maryland 20815, United States
    Not yet recruiting
  • ADARx Clinical Site
    Wheaton, Maryland 20902, United States
    Not yet recruiting
  • ADARx Clinical Site
    Detroit, Michigan 48202, United States
    Not yet recruiting
  • ADARx Clinical Site
    St Louis, Missouri 63141, United States
    Not yet recruiting
  • ADARx Clinical Site
    Las Vegas, Nevada 89128, United States
    Recruiting
  • ADARx Clinical Site
    New York, New York 10029, United States
    Recruiting
  • ADARx Clinical Site
    Cincinnati, Ohio 45236, United States
    Not yet recruiting
  • ADARx Clinical Site
    Columbus, Ohio 43235, United States
    Not yet recruiting
  • ADARx Clinical Site
    Toledo, Ohio 43617, United States
    Not yet recruiting
  • ADARx Clinical Site
    Hershey, Pennsylvania 17033, United States
    Not yet recruiting
  • ADARx Clinical Site
    Capital Federal, Buenos Aires C1425BEN, Argentina
    Not yet recruiting
  • ADARx Clinical Site
    Buenos Aires, Buenos Aires F.D. C1035AAT, Argentina
    Not yet recruiting
  • ADARx Clinical Site
    Adelaide, South Australia 5000, Australia
    Not yet recruiting
  • ADARx Clinical Site
    Vienna, 1090, Austria
    Not yet recruiting
  • ADARx Clinical Site
    Edegem, Antwerpen 2650, Belgium
    Not yet recruiting
  • ADARx Clinical Site
    Sofia, 1000, Bulgaria
    Not yet recruiting
  • ADARx Clinical Site
    Edmonton, Alberta T6G 2R3, Canada
    Not yet recruiting
  • ADARx Clinical Site
    Ottawa, Ontario K1H 1E4, Canada
    Not yet recruiting
  • ADARx Clinical Site
    Montreal, Quebec H2W 1R7, Canada
    Not yet recruiting
  • ADARx Clinical Site
    Beijing, 100730, China
    Not yet recruiting
  • ADARx Clinical Site
    Harbin, 150001, China
    Not yet recruiting
  • ADARx Clinical Site
    Zhengzhou, 450003, China
    Not yet recruiting
  • ADARx Clinical Site
    Split, 21000, Croatia
    Not yet recruiting
  • ADARx Clinical Site
    Zagreb, 10000, Croatia
    Not yet recruiting
  • ADARx Clinical Site
    Hradec Králové, 500 05, Czechia
    Recruiting
  • ADARx Clinical Site
    Prague, 15000, Czechia
    Not yet recruiting
  • ADARx Clinical Site
    Nice, Alpes-Maritimes 06300, France
    Not yet recruiting
  • ADARx Clinical Site
    Tours, Indre-et-Loire 37000, France
    Not yet recruiting
  • ADARx Clinical Site
    Montpellier, 34295, France
    Not yet recruiting
  • ADARx Clinical Site
    Paris, 75012, France
    Not yet recruiting
  • ADARx Clinical Site
    Tübingen, Baden-Wurttemberg 72076, Germany
    Not yet recruiting
  • ADARx Clinical Site
    Hong Kong, 111, Hong Kong
    Not yet recruiting
  • ADARx Clinical Site
    Budapest, 1088, Hungary
    Not yet recruiting
  • ADARx Clinical Site
    Ashkelon, 7830604, Israel
    Not yet recruiting
  • ADARx Clinical Site
    Tel Aviv, 5262100, Israel
    Not yet recruiting
  • ADARx Clinical Site
    Lodz, 92-213, Poland
    Not yet recruiting
  • ADARx Clinical Site
    Barcelona, 08907, Spain
    Not yet recruiting
  • ADARx Clinical Site
    Madrid, 28007, Spain
    Not yet recruiting
  • ADARx Clinical Site
    Taichung, 40705, Taiwan
    Not yet recruiting
  • ADARx Clinical Site
    Cambridge, CB2 0QQ, United Kingdom
    Not yet recruiting
  • ADARx Clinical Site
    Cardiff, CF14 4YS, United Kingdom
    Not yet recruiting
  • ADARx Clinical Site
    London, E1 1BB, United Kingdom
    Not yet recruiting
  • ADARx Clinical Site
    Southampton, SO16 6YD, United Kingdom
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jun 2030, 50 months after the start.

Of 46 industry-sponsored phase 3 interventional studies under Angioedemas, Hereditary, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 33. This study's planned 50 months is above that.

Counting every sponsor, half of 46 studies reached it within 22 months; a quarter within 16 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2026
First posted
Feb 23, 2026
StartActual
Apr 2, 2026
Primary completionEst.
Jun 30, 2030
CompletionEst.
Jun 30, 2030
Last update
Sep 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07428499
Lead sponsor
ADARx Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Feb 23, 2026
Start date
Apr 2, 2026
Primary completion
Jun 30, 2030 (estimated)
Completion
Jun 30, 2030 (estimated)
Last update
Sep 4, 2026

Study contacts

Lupe Gallegos
Contact
info@adarx.com
877-232-7974
Lauge Farnaes, MD
study director · ADARx Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Onvuzosiran sodium

Start the discussion